From the smallest biotech to the biggest pharmaceutical stock The Motley Fool's Market Check-Up covers the health care sector's biggest headlines, hottest market movers, and Obamacare's ongoing rollout.

In this segment from Monday's episode, health-care analyst David Williamson discusses Shire (NASDAQ:SHPG), a biopharmaceutical company focusing on rare diseases, that just beat out several rivals with its bid of $4.2 billion to acquire ViroPharma (NASDAQ:VPHM). ViroPharma sells the successful hereditary angioedema drug Cinryze, which is used in prophylactic treatment of the disease. Shire sees this as an immediately complementary fit with its drug Firazyr, which is for patients already suffering from the active disease.

In the video, David discusses why the deal is good for Shire, why he doesn't see critics' concerns over the deal as anything investors should worry about, and whether he likes the stock from here.

Alison Southwick and David Williamson have no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.